Recent Developments in Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) Could Push Shares Higher


Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) was up significantly recently, returning over 250% YTD. Moreover, CNBX was up over 2,500% over the past year recently. Now, the company recently announced its addition of highly respected professionals to its board of advisors, and these include: Dr. Gil Feiler, Dr. Martin Burow, Dr.Tal Mofkadi, Prof. Amos Toren and Dr. Sigalit Ariely-Portnoy.

Cannabics Pharmaceuticals Inc is a publicly-traded company based in the U.S., and it is dedicated to the development of personalized anti-cancer and palliative treatments. Cannabics Pharmaceuticals’ research and development is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. That said, Cannabis Pharmaceuticals Inc primarily focuses on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, and utilizing advanced screening systems and personalized bioinformatics tools.

When speaking on the newest additions to its board Eyal Ballan, CTO of Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) said, “We are honored to have the newly appointed members on our team and sharing the research on the therapeutic values of cannabinoids.”

Additionally, Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc, said, “The combination of scientific and financial and regulatory knowledge in our board gives us the tools to make well educated decisions as we continue to evolve further in making our vision relevant and accessible to cancer patients worldwide.”

In addition to adding professionals that would provide guidance to Cannabics Pharmaceuticals Inc, the company recently announced the initial commercialization of cannabinoids-based personalized diagnostics for cancer patients. These diagnostic tests are based on liquid biopsies for any type of cancer patient. That said, this would help doctors make well-informed decisions when it comes to cancer patients.



That in mind, the company started to commercialize its products recently, in which 10 of the first patients’ liquid biopsies would be tested using Cannabics Pharmaceuticals’ technology. The company aims to make this technology and service widely available to cancer patients in Canada, Europe, and the U.S. Moreover, the company collaborated with Cancer Hope Israel, which specializes in providing checks of effectiveness of innovative biological medicines and chemotherapy.


These weren’t the only good bits of news the company had recently. Cannabics Pharmaceuticals Inc also announced a new dosage of 5 milligram THC cannabis capsule intended for patients who have not tried cannabis in the past.


The Cannabics 5MG THC capsule is being tested and evaluated by Cannabics Pharma in a clinical study as a palliative treatment, conducted by the oncology department at the Rambam Medical Center in Israel, which is under strict regulations by the ministry of health.

Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, “Our vision is to embrace the natural medicinal properties of cannabis utilizing the diversity of active compounds to fight cancer in its manifestation in each individual patient”.

With that in mind, Cannabics Pharmaceuticals’ products and services could be widely received, which would translate to higher profits, and potentially higher returns for shareholders.
Cannabics Pharma CEO, stated, “The majority of our cancer trial patients have no previous experience with Cannabis and hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations.”


Cannabics Pharmaceuticals Inc added some new members to its board of advisors, which should help the company in expanding its business and deal with regulatory issues in the industry. That said, CNBX could still run higher, despite being up over 200% recently. The stock could move and run higher after these recent developments. If you’re into pot stocks, you’ll want to stay up to date on CNBX. Now, you don’t have to stare at your screens all day for that, all you have to do is enter your email to subscribe to our 100% free newsletter below to get the latest on CNBX.